Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents

• Published in: Journal for immunotherapy of cancer Vol. 10; no. 3; p. e004043
• Main Authors: Turiello, Roberta, Capone, Mariaelena, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Azzaro, Rosa, Del Gaudio, Pasquale, Simeone, Ester, Sorrentino, Antonio, Ascierto, Paolo A, Morello, Silvana
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.03.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate - therapeutic use; Antibodies; B7-H1 Antigen - metabolism; Basic Tumor Immunology; Biomarkers; Biotechnology; Blood & organ donations; Cancer; Cancer therapies; Clinical trials; Enzymes; Flow cytometry; GPI-Linked Proteins; Humans; Immunotherapy; Ligands; Lymphocytes - metabolism; Melanoma; Melanoma - drug therapy; Metastasis; Monoclonal antibodies; Nivolumab - pharmacology; Nivolumab - therapeutic use; Phosphatase; Pilot Projects; Proteins; Retrospective Studies; adenosine; melanoma; immunotherapy

BackgroundCD73 is an ectonucleotidase producing the immunosuppressor mediator adenosine. Elevated levels of circulating CD73 in patients with cancer have been associated with disease progression and poor response to immunotherapy. Immunosuppressive pathways associated with exosomes can affect T-cell...